申请人:Norvartis AG
公开号:US20170088545A1
公开(公告)日:2017-03-30
The present invention provides a compound of formula I
The compounds of formula I demonstrate properties as Smurf-1 inhibitors and are thus useful in the treatment of a range of disorders, particularly pulmonary arterial hypertension.